Elyar Sadeghi-Hokmabadi

Elyar Sadeghi-Hokmabadi


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2021 in Neurology
Verified
Journal Article
Closed access
PDF file
RNRaul G. Nogueira
Raul G. Nogueira
MQMuhammad M. Qureshi
Muhammad M. Qureshi
MAMohamad Abdalkader
Mohamad Abdalkader
SMSheila Ouriques Martins
Sheila Ouriques Martins
HYHiroshi Yamagami
Hiroshi Yamagami
ORon behalf of the SVIN COVID-19 Global Stroke Registry
on behalf of the SVIN COVID-19 Global Stroke Registry
Objective To measure the global impact of COVID-19 pandemic on volumes of IV thrombolysis (IVT), IVT transfers, and stroke hospitalizations over 4 months at the height of the pandemic (March 1 to June 30, 2020) compared with 2 control 4-month periods. Methods We conducted a cross-sectional, observational, retrospective study across 6 continents, 70 countries, and 457 stroke centers. Diagnoses were identified by their ICD-10 codes or classifications in stroke databases. Results There were 91,373 stroke admissions in the 4 months immediately before compared to 80,894 admissions during the pandemic months, representing an 11.5% (95% confidence interval [CI] −11.7 to −11.3, p < 0.0001) decline. There were 13,334 IVT therapies in the 4 months preceding compared to 11,570 procedures during the pandemic, representing a 13.2% (95% CI −13.8 to −12.7, p < 0.0001) drop. Interfacility IVT transfers decreased from 1,337 to 1,178, or an 11.9% decrease (95% CI −13.7 to −10.3, p = 0.001). Recovery of stroke hospitalization volume (9.5%, 95% CI 9.2–9.8, p < 0.0001) was noted over the 2 later (May, June) vs the 2 earlier (March, April) pandemic months. There was a 1.48% stroke rate across 119,967 COVID-19 hospitalizations. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was noted in 3.3% (1,722/52,026) of all stroke admissions. Conclusions The COVID-19 pandemic was associated with a global decline in the volume of stroke hospitalizations, IVT, and interfacility IVT transfers. Primary stroke centers and centers with higher COVID-19 inpatient volumes experienced steeper declines. Recovery of stroke hospitalization was noted in the later pandemic months.

1 October 2013 in Complementary Therapies in Medicine
Verified
Journal Article
Closed access
SRSoheila Rezapour-Firouzi
Soheila Rezapour-Firouzi
SASeyed Rafie Arefhosseini
Seyed Rafie Arefhosseini
FMFarhoudi Mehdi
Farhoudi Mehdi
EMEbrahimi-Mamaghani Mehrangiz
Ebrahimi-Mamaghani Mehrangiz
Behzad BaradaranBehzad Baradaran
Behzad Baradaran
FZFatemeh Zamani
Fatemeh Zamani

1 November 2013 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
DODarioush Savadi Oskouei
Darioush Savadi Oskouei
RRReza Rikhtegar
Reza Rikhtegar
MHMazyar Hashemilar
Mazyar Hashemilar
HSHomayoun Sadeghi-Bazargani
Homayoun Sadeghi-Bazargani
MSMohsen Sharifi-Bonab
Mohsen Sharifi-Bonab
ESEhsan Sharifipour
Ehsan Sharifipour

24 January 2023 in Neurology
Verified
Journal Article
Closed access
PDF file
Thanh N NguyenThanh N Nguyen
Thanh N Nguyen
MQMuhammad M. Qureshi
Muhammad M. Qureshi
PKPiers Klein
Piers Klein
HYHiroshi Yamagami
Hiroshi Yamagami
RMRobert Mikulik
Robert Mikulik
TRthe SVIN COVID-19 Global Stroke Registry
the SVIN COVID-19 Global Stroke Registry
Background and Objectives Declines in stroke admission, IV thrombolysis (IVT), and mechanical thrombectomy volumes were reported during the first wave of the COVID-19 pandemic. There is a paucity of data on the longer-term effect of the pandemic on stroke volumes over the course of a year and through the second wave of the pandemic. We sought to measure the effect of the COVID-19 pandemic on the volumes of stroke admissions, intracranial hemorrhage (ICH), IVT, and mechanical thrombectomy over a 1-year period at the onset of the pandemic (March 1, 2020, to February 28, 2021) compared with the immediately preceding year (March 1, 2019, to February 29, 2020). Methods We conducted a longitudinal retrospective study across 6 continents, 56 countries, and 275 stroke centers. We collected volume data for COVID-19 admissions and 4 stroke metrics: ischemic stroke admissions, ICH admissions, IVT treatments, and mechanical thrombectomy procedures. Diagnoses were identified by their ICD-10 codes or classifications in stroke databases. Results There were 148,895 stroke admissions in the 1 year immediately before compared with 138,453 admissions during the 1-year pandemic, representing a 7% decline (95% CI [95% CI 7.1–6.9]; p < 0.0001). ICH volumes declined from 29,585 to 28,156 (4.8% [5.1–4.6]; p < 0.0001) and IVT volume from 24,584 to 23,077 (6.1% [6.4–5.8]; p < 0.0001). Larger declines were observed at high-volume compared with low-volume centers (all p < 0.0001). There was no significant change in mechanical thrombectomy volumes (0.7% [0.6–0.9]; p = 0.49). Stroke was diagnosed in 1.3% [1.31–1.38] of 406,792 COVID-19 hospitalizations. SARS-CoV-2 infection was present in 2.9% ([2.82–2.97], 5,656/195,539) of all stroke hospitalizations. Discussion There was a global decline and shift to lower-volume centers of stroke admission volumes, ICH volumes, and IVT volumes during the 1st year of the COVID-19 pandemic compared with the prior year. Mechanical thrombectomy volumes were preserved. These results suggest preservation in the stroke care of higher severity of disease through the first pandemic year. Trial Registration Information This study is registered under NCT04934020.

24 July 2012 in ISRN Neurology
Verified
Journal Article
Open access
PDF file
HAHormoz Ayromlou
Hormoz Ayromlou
MTMohammad K. Tarzamni
Mohammad K. Tarzamni
MDMohammad Hossein Daghighi
Mohammad Hossein Daghighi
MPMohammad Zakaria Pezeshki
Mohammad Zakaria Pezeshki
MYMohammad Yazdchi
Mohammad Yazdchi
KGKamyar Ghabili
Kamyar Ghabili
Aim. To evaluate the diagnostic value of ultrasonography and magnetic resonance imaging (MRI) in patients with ulnar neuropathy at the elbow (UNE). Methods. We prospectively performed electrodiagnostic, ultrasonographic, and MRI studies in UNE patients and healthy controls. Three cross-sectional area (CSA) measurements of the ulnar nerve at multiple levels along the arm and maximum CSA(-max) were recorded. Results. The ulnar nerve CSA measurements were different between the UNE severity grades (P<0.05). CSA-max had the greatest sensitivity (93%) and specificity (68%). Moreover, CSA-max ≥10 mm2 defined the severe UNE cases (sensitivity/specificity: 82%/72%). In MRI, ulnar nerve hyperintensity had the greatest sensitivity (90%) and specificity (80%). Conclusion. Ultrasonography using CSA-max is sensitive and specific in UNE diagnosis and discriminating the severe UNE cases. Furthermore, MRI particularly targeting at increased signal of the ulnar nerve can be a useful diagnostic test of UNE.

28 April 2017 in Neurorehabilitation and Neural Repair
Verified
Journal Article
Closed access
DODaryoush Savadi Oskouie
Daryoush Savadi Oskouie
ESEhsan Sharifipour
Ehsan Sharifipour
HBHomayoun Sadeghi Bazargani
Homayoun Sadeghi Bazargani
MHMazyar Hashemilar
Mazyar Hashemilar
MNMasoud Nikanfar
Masoud Nikanfar
SGSamad E. J. Golzari
Samad E. J. Golzari
Background and purpose. Ischemic stroke (IS) is one of the main causes of death and disability in the adult population, and recovery from it is a major health concern worldwide. The aim of the present study was to evaluate the effectiveness of citalopram on 3-mounth outcome of nondepressed acute IS patients. Methods. In a randomized, placebo-controlled clinical trial, 144 patients with acute IS were studied for 3 months. In one group, the patients received oral citalopram 20 mg (once daily), and in the other group, they received placebo. All patients received standard care, including physiotherapy. Patients with depression were excluded throughout the study. The primary outcome of the study was set to a 50% reduction in the 3-month National Institutes of Health Stroke Scale compared with the baseline scores (Clinical Trial Registration URL: http://www.irct.ir; Unique identifier: IRCT201203192150N2). Results. The mean age of patients was 66.4 years. Of 144 eligible patients, 15 patients died (4 in the citalopram and 11 in the placebo group), and 21 patients did not complete the study follow-up period (10 in the citalopram and 11 in the placebo group). The primary outcome of the study was achieved in 57 patients (79%) in the citalopram and 39 patients (54%) in the placebo group (P < .001), with risk ratio and number needed to treat of 2 (CI = 1.2-3) and 4 (CI = 2.5-8.6), respectively. No major adverse events were found in either group. Conclusions. Citalopram is a safe and tolerable medication in patients with acute IS, which could improve the outcome in these patients.